Dag S. Halvorsen
Papers
1
Total Citations
3
H-Index
1
About
Dag S. Halvorsen is a leading urologic oncologist whose research centers on testicular cancer, with a particular focus on optimizing surgical management for seminoma. As a key member of the SWENOTECA (Swedish Norwegian Testicular Cancer Group), Halvorsen has been instrumental in advancing treatment paradigms for stage IIA-IIB seminoma. His landmark work, "The Early Results of the SWENOTECA Introduction of Primary Retroperitoneal Lymph Node Dissection (RPLND) in Seminoma Stage IIA-IIB ≤ 3cm," published in the *Journal of Urology* (2023), represents a pivotal shift in clinical practice. This study demonstrates that primary RPLND can effectively reduce the need for adjuvant chemotherapy in patients with limited retroperitoneal disease, thereby minimizing long-term toxicity while maintaining excellent oncologic outcomes. Though recently published, this work has already garnered 3 citations, signaling its growing influence in the field. Halvorsen’s contributions are reshaping the management of testicular cancer, offering patients a surgery-first approach that spares them the cumulative risks of radiation and chemotherapy. His research exemplifies the power of collaborative Nordic clinical trials in driving evidence-based change, and he continues to be a vital voice in genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1